Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 3/20 | 0.36 |
| ▸ | PLG | P00747 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675996 | 1.00 | S1PR5 (0.38) | S1PR5GCGRPLGPLAUPLAT | |
| SCHEMBL1676115 | 0.94 | PLG (0.38) | S1PR5GCGRPLGPLAUPLAT | |
| SCHEMBL1676119 | 0.94 | PLG (0.38) | S1PR5GCGRPLGPLAUPLAT | |
| SCHEMBL1676204 | 0.90 | S1PR5 (0.37) | S1PR5GCGRGRIN2BSLC13A5 | |
| SCHEMBL1676201 | 0.90 | S1PR5 (0.37) | S1PR5GCGRGRIN2BSLC13A5 | |
| SCHEMBL1676177 | 0.88 | CNR1 (0.40) | S1PR5GCGRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1676181 | 0.88 | CNR1 (0.40) | S1PR5GCGRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1481397 | 0.86 | S1PR5 (0.42) | S1PR5GCGRTRPM2SLC13A5 | |
| SCHEMBL1481399 | 0.86 | S1PR5 (0.42) | S1PR5GCGRTRPM2SLC13A5 | |
| SCHEMBL1676133 | 0.85 | CNR1 (0.39) | S1PR5GCGRPLGPLAUPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | S1PR5 3261/4885GCGR 610/4885PLG 2773/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | S1PR5 3261/4885GCGR 610/4885PLG 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.